EGFR and neoplasm: A new type of a bispecific antibody that engages simultaneously EGFR on tumor cells and CD3 on T cells was designed to prevent its binding to EGFR expressed in healthy tissues (a masked form) but to become activated by proteases (an unmasked form) in the tumor microenvironment.